MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$42,109K
EPS
-$0.24
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Collaboration revenue
-
-
838
1,225
Collaboration revenue related party
1,154
856
-
-
Research and development
33,397
34,105
34,709
43,990
General and administrative
11,042
17,405
14,737
11,208
Total operating expenses
44,439
51,510
49,446
55,198
Loss from operations
-43,285
-50,654
-48,608
-53,973
Interest income
788
1,021
1,083
1,141
Accretion (amortization) of investments
333
460
858
752
Change in fair value of short-term investment related party
0
0
539
1,454
Other income, net
55
51
49
44
Total other income, net
1,176
1,532
2,529
3,391
Net loss attributable to common stockholders, basic
-42,109
-49,122
-46,079
-50,582
Net loss attributable to common stockholders, diluted
-42,109
-49,122
-
-50,582
Basic EPS
-0.24
-0.28
-0.264
-0.32
Diluted EPS
-0.24
-0.28
-0.264
-0.32
Basic Average Shares
177,224,892
177,096,225
174,460,517
160,503,183
Diluted Average Shares
177,224,892
177,096,225
174,460,517
160,503,183
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
attributable to common...
-$42,109K
(19.93%↑ Y/Y)
Interest income
$788K
(6.06%↑ Y/Y)
Accretion (amortization)
of investments
$333K
(-37.17%↓ Y/Y)
Other income, net
$55K
(205.56%↑ Y/Y)
Net loss
attributable to common...
-$42,109K
(19.93%↑ Y/Y)
Total other income,
net
$1,176K
(49.62%↑ Y/Y)
Loss from operations
-$43,285K
(18.91%↑ Y/Y)
Collaboration revenue related
party
$1,154K
Total operating
expenses
$44,439K
(-18.45%↓ Y/Y)
Research and development
$33,397K
(-19.28%↓ Y/Y)
General and
administrative
$11,042K
(-15.82%↓ Y/Y)
Buy us a coffee
Prime Medicine, Inc. (PRME)
Prime Medicine, Inc. (PRME)